Ridgewood Investments LLC Acquires 568 Shares of Johnson & Johnson (NYSE:JNJ)

Ridgewood Investments LLC grew its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 14.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,373 shares of the company’s stock after buying an additional 568 shares during the quarter. Ridgewood Investments LLC’s holdings in Johnson & Johnson were worth $632,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Legacy Private Trust Co. raised its holdings in shares of Johnson & Johnson by 8.4% in the 4th quarter. Legacy Private Trust Co. now owns 39,173 shares of the company’s stock valued at $5,665,000 after purchasing an additional 3,047 shares during the period. Douglas Lane & Associates LLC raised its holdings in shares of Johnson & Johnson by 1.1% in the 4th quarter. Douglas Lane & Associates LLC now owns 599,386 shares of the company’s stock valued at $86,683,000 after purchasing an additional 6,526 shares during the period. InvesTrust bought a new stake in shares of Johnson & Johnson in the 4th quarter valued at about $6,355,000. Fulton Bank N.A. raised its holdings in Johnson & Johnson by 7.8% in the 4th quarter. Fulton Bank N.A. now owns 47,550 shares of the company’s stock valued at $6,877,000 after acquiring an additional 3,427 shares during the period. Finally, Innova Wealth Partners bought a new position in Johnson & Johnson in the 4th quarter valued at about $416,000. 69.55% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Johnson & Johnson news, Director Mark A. Weinberger bought 1,000 shares of the firm’s stock in a transaction dated Thursday, December 12th. The stock was bought at an average cost of $147.22 per share, with a total value of $147,220.00. Following the completion of the transaction, the director now directly owns 1,000 shares in the company, valued at approximately $147,220. The trade was a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Price Performance

NYSE:JNJ traded up $0.84 on Friday, hitting $143.11. The company had a trading volume of 3,299,437 shares, compared to its average volume of 7,066,686. The stock has a market capitalization of $344.55 billion, a price-to-earnings ratio of 20.71, a PEG ratio of 2.52 and a beta of 0.51. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. The firm has a 50 day moving average of $150.03 and a two-hundred day moving average of $156.04. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $168.85.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, beating the consensus estimate of $2.21 by $0.21. The business had revenue of $22.47 billion during the quarter, compared to the consensus estimate of $22.17 billion. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The firm’s revenue was up 5.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.66 EPS. On average, research analysts anticipate that Johnson & Johnson will post 9.94 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 3.47%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is presently 71.78%.

Analyst Ratings Changes

Several research analysts have weighed in on JNJ shares. Wells Fargo & Company increased their price target on shares of Johnson & Johnson from $163.00 to $166.00 and gave the company an “equal weight” rating in a report on Wednesday, October 16th. Bank of America restated a “neutral” rating and set a $166.00 target price on shares of Johnson & Johnson in a research report on Tuesday, December 10th. Morgan Stanley increased their target price on shares of Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 16th. Wolfe Research began coverage on shares of Johnson & Johnson in a research report on Friday, November 15th. They set an “outperform” rating and a $190.00 target price on the stock. Finally, Guggenheim increased their target price on shares of Johnson & Johnson from $156.00 to $162.00 and gave the stock a “neutral” rating in a research report on Wednesday, November 6th. Seven research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $174.71.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.